NCT05476757View on ClinicalTrials.gov

Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

March 31, 2026

Conditions
Dengue
Interventions
BIOLOGICAL

rDEN2Δ30-7169

rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.

Trial Locations (1)

10700

Siriraj Hospital, Bangkok Noi

All Listed Sponsors
lead

Mahidol University

OTHER

NCT05476757 - Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169. | Biotech Hunter | Biotech Hunter